Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Inactivated Vaccines Market Size From 2025 to 2034?
The size of the inactivated vaccines market has been steadily expanding in recent times. It is anticipated to elevate from $6.19 billion in 2024 to $6.37 billion in 2025, with a compound annual growth rate (CAGR) of 2.8%. The previous growth can be credited to efforts to wipe out polio, influenza immunization schemes, the emergence of infectious diseases, and regulatory authorizations.
The market size of the inactivated vaccines is projected to experience consistent expansion in the coming years. By 2029, it is anticipated to reach $7.58 billion with a Compound Annual Growth Rate (CAGR) of 4.5%. Factors contributing to this anticipated augmentation in the outlook period include preparedness for pandemics, increased vaccine coverage, advancements in biomanufacturing, and health equity campaigns. The prediction period will also witness significant trends such as the use of mRNA vaccine platforms, combination vaccines, thermostable vaccines, and the introduction of digital vaccine passports.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theInactivated Vaccines Market?
The escalating occurrence of infectious diseases is predicted to drive the expansion of the inactivated vaccine market. Pathogens, including bacteria, viruses, fungi or parasites, cause infectious diseases which can transmit between people, leading to a variety of symptoms and health conditions, such as tuberculosis. Inactivated vaccines, which utilize non-living pathogens to trigger an immune response, are highly effective in preventing diseases like polio, hepatitis A and influenza. For example, in November 2023, the Centers for Disease Control and Prevention, a national public health organization based in the US, reported an increase in tuberculosis cases within the country from 8,320 in 2022 to 9,615 in 2023, which is an increase of 1,295 cases. Therefore, the escalating occurrence of infectious diseases is fueling the expansion of the inactivated vaccine market.
Which Segments in the Inactivated Vaccines Offer the Most Growth?
The inactivated vaccines market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine
2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
Subsegments:
1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine
2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp
What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theInactivated Vaccines Market?# Market?
North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Current Market Growth and Trends in the Inactivated Vaccines Industry?
Leading corporations in the inactivated vaccines market are pioneering new and improved inactivated vaccines in an attempt to retain their market status. This type of vaccine includes deactivated virus particles, bacteria, or alternative pathogens, grown in a culture and then killed to eliminate their capacity to produce disease. To illustrate, in January 2022, GSK PLC, a pharmaceutical and biotechnology firm based in the UK, launched an innovative inactivated vaccine called Shingrix to help protect against shingles (Herpes zoster). Shingrix, a non-live, recombinant subunit adjuvanted vaccine, is given intramuscularly in two doses. Initially, the vaccine was recommended for individuals aged 50 and above, but its use has recently been extended to include those aged 18 and above who are at an increased risk of contracting shingles due to known illness-driven or treatment-driven immunodeficiency or immunosuppression.
View the full report here:
https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report
What Are the Key Elements That Define the Inactivated Vaccines Market?
Inactivated vaccines, also known as killed vaccines, are a type of vaccine that contains viruses or bacteria that have been killed or inactivated using heat, chemicals, or radiation. These vaccines are designed to stimulate an immune response without causing disease in the vaccinated individual.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13018
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model